Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Advice programme

Showing 1 to 19 of 19

TitleReference numberPublishedLast updated
Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosisTA127
Alemtuzumab for treating highly active relapsing–remitting multiple sclerosisTA312
Cladribine for treating relapsing–remitting multiple sclerosisTA616
Multiple sclerosis in adults: managementNG220
Diroximel fumarate for treating relapsing–remitting multiple sclerosisTA794
icobrain ms for active relapsing–remitting multiple sclerosisMIB291
Ponesimod for treating relapsing–remitting multiple sclerosisTA767
Ozanimod for treating relapsing–remitting multiple sclerosisTA706
Ofatumumab for treating relapsing multiple sclerosisTA699
Siponimod for treating secondary progressive multiple sclerosisTA656
Peginterferon beta-1a for treating relapsing–remitting multiple sclerosisTA624
Ocrelizumab for treating primary progressive multiple sclerosisTA585
Percutaneous venoplasty for chronic cerebrospinal venous insufficiency in multiple sclerosisIPG640
Ocrelizumab for treating relapsing–remitting multiple sclerosisTA533
Beta interferons and glatiramer acetate for treating multiple sclerosisTA527
Multiple sclerosisQS108
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosisTA320
Teriflunomide for treating relapsing–remitting multiple sclerosisTA303
Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosisTA254

Results per page

  1. 10
  2. 25
  3. 50
  4. All